New cholesterol drug RN5681 enters first human tests
NCT ID NCT07347678
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called RN5681 in 60 healthy adults to see if it is safe and how the body handles it. Participants receive either a single injection of RN5681 or a placebo. The study also looks at how the drug affects cholesterol levels, but the main focus is safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RN5681 (an investigational drug given as an injection under the skin)
What this could lead to
If successful, this could lead to a new treatment option for lowering high cholesterol, potentially reducing heart disease risk.
What could go wrong
This is an early Phase 1 trial with only 60 healthy volunteers, so it's too soon to know if the drug works or is safe for patients. The main goal is safety, not effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH CHOLESTEROL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Pty Ltd.
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Q-Pharm Pty Ltd.
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact